Search for: "State v. Tri-State Pharmaceutical" Results 1 - 20 of 453
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Jan 2011, 6:29 pm by Sonia Katyal
This week, my colleague, Jeanne Fromer, and myself had the pleasure of hosting a Tri-State conference on Intellectual Property at Fordham Law School. [read post]
12 Sep 2012, 6:14 pm by Mandour & Associates
IPNews® - Johnson & Johnson unit Janssen Pharmaceuticals Inc. won a major patent infringement victory Tuesday when a New Jersey federal judge held that its patent for the popular birth control drug Ortho Tri-Cyclen Lo is valid. [read post]
21 Nov 2012, 12:48 pm by Schachtman
Ortho Pharmaceutical Corp., 788 F.2d 741 (11th Cir. 1986), with Smith v. [read post]
25 Nov 2007, 11:04 am
But the world seems to have overlooked the implications of Thomson v. [read post]
4 Dec 2007, 6:33 pm
Pharmaceutical Resources and Par Pharmaceuticals v. [read post]
Teva Pharmaceuticals USA, Inc., the United States District Court for the District of New Jersey recently ordered that two separate, but related, Hatch-Waxman cases must be tried together. [read post]
Teva Pharmaceuticals USA, Inc., the United States District Court for the District of New Jersey recently ordered that two separate, but related, Hatch-Waxman cases must be tried together. [read post]
Teva Pharmaceuticals USA, Inc., the United States District Court for the District of New Jersey recently ordered that two separate, but related, Hatch-Waxman cases must be tried together. [read post]
17 Nov 2018, 12:10 pm by Schachtman
Indeed, their brief in other places states their opinion that significance testing is not necessary at all: “Testing for significance, however, is often mistaken for a sine qua non of scientific inference. [read post]
22 Apr 2007, 4:39 am
Preemption is a big deal: The feds have tried to preempt state regulation of financial markets, as in Watters v. [read post]
28 Jul 2011, 11:19 am by Bexis
  He didn't file suit, however, until June 2009.Dead to rights under the Texas two-year statute of limitations, plaintiff tried to argue that his claim didn't "accrue" until there was scientific evidence sufficient to satisfy Texas' version of Daubert, which was imposed in Merrell Dow Pharmaceuticals, Inc. v. [read post]